Scientists from Budapest University of Technology and Economics (BME) recently published a study, titled “Bioreduction of N‑(3‑oxobutyl)heterocycles with fexible ring by yeast whole‑cell biocatalysts” in which they explored the bioreduction of N-(3-oxobutyl)heterocycles with (partially) saturated heterocyclic moieties using
whole-cell forms of wild-type yeast strains and commercially available baker’s yeast (Saccharomyces cerevisiae). The enantiopure alcohols produced by biocatalytic reactions are promising chiral fragments with high level of drug-likeness.
We are proud that our R&D Manager, Viktória Bódai could contribute to the study and we are grateful to BME for this cooperation.
